Trial Profile
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary) ; Antiandrogens
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- 04 Oct 2020 Status changed from suspended to completed. This study was previously suspended as Daiichi Sankyo conducting a safety review of PLX3397 programs.
- 29 Nov 2017 Status changed from recruiting to suspended.
- 13 Sep 2017 Planned End Date changed from 1 Jun 2017 to 31 dec 2018.